Metabolic permissiveness: how tissue context shapes cancer

Area of Science:

• Oncology
• Cancer Metabolism
• Systems Biology

Background:

• Cancer metabolism exhibits paradoxical tissue-specific phenotypes despite identical oncogenic mutations.
• Understanding this tissue context selectivity is crucial for targeted cancer therapies.

Purpose of the Study:

• Introduce "metabolic permissiveness" as a framework to explain tissue-specific metabolic phenotypes in cancer.
• Unify understanding of how oncogenic mutations impact cancer metabolism across different tissues.

Main Methods:

• Examined tissue-specific metabolic rewiring driven by key oncogenes (MYC, KRAS), tumor suppressors (p53, PTEN, LKB1), and TCA cycle enzymes (FH, SDH, IDH).
• Analyzed the roles of baseline metabolic architecture, nutrient availability, redox balance, and compensatory pathways.

Main Results:

• Demonstrated that tissue's inherent metabolic capacity (permissiveness) dictates whether mutations lead to selective advantage or metabolic crisis.
• Identified factors like baseline metabolism, nutrient microenvironment, and redox buffering as key determinants of metabolic adaptation.
• Highlighted the influence of the tumor microenvironment on metabolic adaptation and therapeutic vulnerability.

Conclusions:

• Metabolic permissiveness provides a unifying framework for understanding tissue-specific metabolic vulnerabilities in cancer.
• Reveals shared principles governing metabolic adaptation across diverse cancer types.
• Offers a mechanistic basis for developing precision metabolic therapies targeting cancer vulnerabilities.